The androgen receptor and stem cell pathways in prostate and bladder cancers (review).

TitleThe androgen receptor and stem cell pathways in prostate and bladder cancers (review).
Publication TypeJournal Article
Year of Publication2012
AuthorsMarcinkiewicz K, Scotland KB, Boorjian SA, Nilsson EM, Persson JLiao, Abrahamsson PAnders, Allegrucci C, Hughes IA, Gudas LJ, Mongan NP
JournalInt J Oncol
Volume40
Issue1
Pagination5-12
Date Published2012 Jan
ISSN1791-2423
KeywordsFemale, Humans, Male, Neoplastic Stem Cells, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Urinary Bladder Neoplasms
Abstract

Bladder cancer is three times more common in men than in women. However, the physiological basis of the male predominance of bladder cancer remains poorly understood. A higher than expected association of prostate and bladder cancers has also been reported which may indicate a common mechanism of carcinogenesis. Consistent with this, androgens and the androgen receptor (AR) play essential roles in prostate carcinogenesis and are believed to play a role in bladder carcinogenesis. There is also evidence implicating cancer stem cells in prostate and bladder cancers. Indeed putative prostate and bladder cancer stem cells share some common molecular features. We highlight key proteins (CD49f, CD133, PTEN, CD44) which are implicated in both prostate and bladder cancers and are enriched in putative prostate and bladder cancer stem cells. We examine published chromatin immuno-precipitation studies analyzing the genome-wide distribution of the AR to identify AR association with, and by inference potential AR-regulation of, these loci. We discuss recent evidence indicating a role for the AR in the splicing of the key urological stem cell protein CD44. We propose a model whereby aberrant AR regulation of these putative stem cell proteins contributes to malignant transformation of prostate and bladder cells. For these reasons we propose that the relationship between androgens and cancer stem cell associated proteins warrants further investigation.

DOI10.3892/ijo.2011.1212
Alternate JournalInt. J. Oncol.
PubMed ID21956088
PubMed Central IDPMC4371775
Grant ListT32 GM073546 / GM / NIGMS NIH HHS / United States
F31 DE021316 / DE / NIDCR NIH HHS / United States
F31 CA123703 / CA / NCI NIH HHS / United States
F31 CA123703-02 / CA / NCI NIH HHS / United States
T32 GM007739 / GM / NIGMS NIH HHS / United States